Samsung Bioepis lines up Opuviz syringe as European aflibercept rivals multiply

10 August 2026

South Korean biosimilar firm Samsung Bioepis, a wholly owned subsidiary of Samsung Epis Holdings (KRX: 0126Z0), expects to put a pre-filled syringe version of its Eylea copy Opuviz (aflibercept) on the European market in the third quarter, a few months after launching the vial presentation into a field already thick with rivals.

The European Medicines Agency's human medicines committee backed the 40 mg/mL syringe in November 2025 for the same indications as the vial: wet age-related macular degeneration (AMD), visual impairment from macular edema following retinal vein occlusion, diabetic macular edema and myopic choroidal neovascularization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK